Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2024-04-30 Audit Report / Informat…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Jednostkowy raport roczny Pure Biologics S.A. za okres 01.01.2023-31.12.2023 - podpisy
Audit Report / Information Classification · 95% confidence The provided document text consists almost entirely of XML structures detailing digital signatures, certificates (X.509Data), SignedInfo, and references to a file named "PureBiologcsJRR_2023-12-31_pl.xhtml". This structure is characteristic of an electronically signed document, often found within regulatory filings submitted to authorities like the SEC or European equivalents, where the signature block itself is extracted or presented. The presence of multiple, complex digital signatures (including timestamps and issuer information like 'Krajowa Izba Rozliczeniowa S.A.' and 'Narodowy Bank Polski') strongly suggests this is a component of a formal, legally required submission. Since the text does not contain the actual content of a report (like financial statements, management discussion, or meeting minutes) but rather the cryptographic proof of its authenticity, it is not an ER, 10-K, IR, or AGM-R. Given that this is a highly structured, signed component of a filing, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Proxy Statement (PSI), the most appropriate general classification for a document whose primary content is the signature/validation metadata of a filing is the fallback category for miscellaneous regulatory documents: Regulatory Filings (RNS). If the document were the actual report referenced (e.g., the XHTML file), the classification would be different, but here we only have the signature block. FY 2023
2024-04-30 Polish
Jednostkowy raport roczny Pure Biologics S.A. za okres 01.01.2023-31.12.2023
Audit Report / Information Classification · 95% confidence The document text provided is heavily truncated and appears to be the raw HTML/CSS structure generated by a PDF conversion tool (pdf2htmlEX), indicated by tags like 'html', 'head', 'style', and font definitions ('@font-face'). The title tag contains 'PureBiologcsJRR_2023-12-31_pl.xhtml', suggesting it relates to a report from PureBiologics for the period ending December 31, 2023. Given the extremely large character count (over 20 million characters, though truncated), this is likely the full content of a comprehensive financial report, such as an Annual Report (10-K) or an Interim Report (IR), rather than a short announcement. Since the filename suggests a year-end report ('2023-12-31'), the most appropriate classification among the comprehensive reports is the Annual Report (10-K), assuming this is the primary regulatory filing for the full year. FY 2023
2024-04-30 Polish
Lista akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym Zgromadzeniu Pure Biologics S.A. 27 marca 2024 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states that the issuer is providing a list of shareholders who held at least 5% of the votes at an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie or NWZ) held on March 27, 2024. It details the number of shares and corresponding voting percentages for four major shareholders. This content directly relates to the results of a shareholder vote at a general meeting. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-03-27 Polish
Treść uchwał podjętych przez NWZ Pure Biologics S.A. w dniu 27 marca 2024 r.
AGM Information Classification · 98% confidence The document text consists of multiple resolutions ("Uchwała Nr 1/2024", "Uchwała Nr 2/2024", "Uchwała Nr 3/2024") passed by an "Nadzwyczajne Walne Zgromadzenie" (Extraordinary General Meeting or EGM) of Pure Biologics S.A. The resolutions cover the election of the meeting chairman, adoption of the agenda, and approval for the disposal of significant assets. Documents detailing the proceedings, resolutions, and voting results of a General Meeting (whether Annual or Extraordinary) fall under the category of AGM Information, even if the meeting is extraordinary, as it documents the formal decisions made during that assembly. The code AGM-R covers presentations and materials shared during the Annual General Meeting (AGM), and by extension, materials detailing the resolutions and voting results of any formal General Meeting.
2024-03-27 Polish
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie Pure Biologics S.A. 27 marca 2024 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document text is very short (625 characters) and explicitly states that the Management Board ('Zarząd') is enclosing ('przekazuje w załączeniu') the content of the resolutions ('treść uchwał') adopted by the Extraordinary General Meeting ('Nadzwyczajne Walne Zgromadzenie Emitenta' or NWZ) held on March 27, 2024. This structure—announcing the attachment/enclosure of meeting resolutions—is characteristic of reporting the results of a shareholder vote. The most specific category for official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM/EGM, DVA specifically covers the *results* of the vote, which is what is being provided.
2024-03-27 Polish
Lista akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym Zgromadzeniu Pure Biologics S.A. 18 marca 2024 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is providing a 'wykaz akcjonariuszy Emitenta posiadających co najmniej 5% liczby głosów na Nadzwyczajnym Walnym Zgromadzeniu Spółki' (a list of shareholders holding at least 5% of the votes at the Extraordinary General Meeting (EGM)). This content directly relates to the results of a shareholder vote at a general meeting. The definition for Declaration of Voting Results & Voting Rights Announcements (DVA) covers 'Official results from shareholder votes at any general meeting (AGM or EGM)'. Although the document lists major shareholders present at the meeting, the context is the outcome/participation in that specific vote, making DVA the most appropriate classification.
2024-03-18 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.